Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

— Improved loss from operations by 81% —

— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections —

Read more at prnewswire.com